Study is the first to experimentally determine which byproducts from the mutation of tumors have the ability to provoke the immune system into recognizing and killing cancer cells in multiple myeloma patients

Findings suggest that artificial intelligence in the medical space must be carefully tested for performance across a wide range of populations

A comprehensive RNA and DNA sequencing platform benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them

“This research provides insight into the mechanisms of early cancer spread and may shed light into unexplained phenomena—among them, why as many as five percent of cancer patients worldwide have cancer metastases but no original tumor"